Published by Inorganic Ventures | Sample Preparation & Analytical Standards

In elemental impurities testing, the analysis is only as good as the sample preparation that precedes it. A perfectly calibrated ICP-OES or ICP‑MS system will produce unreliable data if the sample has not been fully digested, if volatile analytes have been lost during preparation, or if contamination has been introduced through reagents or labware.

Microwave-assisted digestion in sealed, pressurised vessels has become the standard sample preparation technique for pharmaceutical matrices requiring elemental impurities analysis under USP <232>, USP <233>, and USP <2232>. It addresses the fundamental challenge of pharmaceutical sample preparation: completely decomposing complex organic matrices while retaining volatile elements like arsenic and mercury at quantifiable concentrations.

This post provides a practical, step-by-step framework for laboratories implementing or optimising microwave digestion workflows for USP-compliant pharmaceutical testing.

Why Microwave Digestion Is the Preferred Approach

Pharmaceutical products encompass an enormous range of matrices—tablets, capsules, creams, gels, injectables, botanicals, active pharmaceutical ingredients (APIs), and excipients. Many of these resist conventional open-vessel acid digestion because of their high organic content, insoluble fillers (such as microcrystalline cellulose or titanium dioxide), or heat-sensitive components that require controlled decomposition.

Closed-vessel microwave digestion solves these problems by operating under elevated temperature and pressure, fundamentally changing the digestion chemistry:

•   Complete matrix decomposition: Sealed vessels allow temperatures above the atmospheric boiling point of the acid mixture (typically 180–220 °C), breaking down matrices that resist conventional digestion. This is critical—incomplete digestion leaves analyte elements bound in undissolved residue, producing artificially low results.

•   Volatile element retention: This is the single most important advantage for USP testing. Arsenic and mercury—two of the four Class 1 elements mandated by USP <232>—are volatile and prone to loss during open-vessel heating. Sealed microwave vessels eliminate this pathway entirely.

•   Reduced contamination: Vessels remain sealed from loading through cooling, minimising exposure to airborne particulates and laboratory contaminants. For trace-level analysis at parts-per-billion concentrations, this matters significantly.

•   Faster throughput: A complete digestion cycle—including ramp, hold, and cool-down—typically takes 45–60 minutes, compared to several hours for open-vessel hot-plate methods.

•   Reproducibility: Automated temperature and pressure control removes operator variability, supporting the precision requirements of USP <233> (≤20% RSD).

For labs performing analysis by ICP‑OES or ICP‑MS, the improved digestion completeness translates directly to better spike recoveries and more confident compliance determinations. For background on how elemental impurities testing fits into the broader analytical workflow, see our overview of how elemental impurities testing is carried out.

The Regulatory Framework: USP Chapters Governing Sample Preparation

USP does not mandate a specific digestion technique. Instead, it defines performance-based criteria that the chosen sample preparation method must meet. The three most relevant chapters are:

USP <232>: Elemental Impurities—Limits

USP <232> establishes Permitted Daily Exposure (PDE) limits for 24 elemental impurities across oral, parenteral, and inhalational routes of administration. The Class 1 elements—arsenic, cadmium, lead, and mercury—must be evaluated for every drug product. Understanding these limits is essential because they define what your digestion and analysis workflow must be capable of detecting. 

USP <233>: Elemental Impurities—Procedures

USP <233> is where sample preparation requirements become explicit. It specifies two analytical procedures (ICP‑OES and ICP‑MS) and requires the entire method—including the digestion step—to demonstrate:

Table 1: USP <233> validation requirements applicable to the digestion and analysis method.

Microwave digestion is widely adopted precisely because it reliably meets these benchmarks, particularly the accuracy criterion—the complete matrix destruction and sealed-vessel design ensure quantitative recovery of all target elements.

USP <2232>: Elemental Contaminants in Dietary Supplements

For laboratories testing dietary supplements and botanical products, USP <2232> extends the Class 1 elemental impurity requirements (As, Cd, Hg, Pb) to finished supplement dosage forms. These matrices are often the most challenging to digest—high organic loads, complex plant-derived compounds, and mineral-rich formulations—making microwave digestion effectively the only viable approach for consistent results.

Step-by-Step Microwave Digestion Workflow for Pharmaceutical Samples

Step 1: Sample Selection and Homogenisation

Solid dosage forms (tablets, capsules, powders) should be ground to a fine, uniform particle size using a clean agate or PTFE mortar and pestle. Capsule shells can be included or excluded depending on the scope of testing. Liquid and semi-solid formulations (syrups, creams, gels) should be thoroughly homogenised before subsampling.

USP does not prescribe a specific sample mass, but 50–300 mg is typical for microwave digestion. The goal is to balance sufficient sample mass for representative analysis against excessive organic loading that could produce dangerous pressure spikes during digestion. For excipients with very high organic content (e.g., starch, cellulose-based fillers), err toward the lower end of this range.

Step 2: Reagent Selection

Reagent choice is not arbitrary—it directly affects digestion completeness, analyte stability, spectral interferences, and blank levels. The standard approach uses:

•   Nitric acid (HNO₃) as the primary reagent – HNO₃ is the preferred acid for ICP-based analysis because its oxidising properties decompose organic matrices effectively, and nitrate salts are highly soluble. Critically, it avoids the chloride-based polyatomic interferences (particularly ⁴⁰Ar³⁵Cl⁺ on arsenic at m/z 75) that are introduced by hydrochloric acid. Most analysts prefer concentrated (65–70%) trace-metal or ICP-grade HNO₃.

•   Hydrogen peroxide (H₂O₂) as a secondary oxidant – H₂O₂ (30%, Suprapur or equivalent grade) is added to aid the oxidation of difficult organic matrices. It is particularly useful for high-carbon samples like botanical supplements or cellulose-heavy excipients. A typical ratio is 5–7 mL HNO₃ + 1–2 mL H₂O₂.

•   Hydrochloric acid (HCl) – use with caution – HCl can improve the stability of certain analytes (notably mercury and gold) in solution, but it introduces spectral interferences on arsenic and chromium in ICP‑MS. If HCl is necessary, collision/reaction cell (CRC) technology in helium KED mode is required. For guidance on acid selection, see our acid matrix selection guide for ICP.

Reagent purity is non-negotiable. At the sub-ppb detection levels required for USP <232> compliance, even trace impurities in the digestion acid will compromise blank levels and inflate detection limits. Use only ICP-grade or Suprapur reagents, and run reagent blanks with every batch. For more on blank management and calibration best practices, see our guide to calibration curves.

Step 3: Vessel Selection

The vessel material and design must withstand the temperature and pressure conditions required for complete digestion:

•   High-pressure PTFE (TFM) vessels are the standard choice for pharmaceutical digestion. They offer excellent chemical resistance, low blank contribution, and can tolerate temperatures up to 260 °C and pressures up to 100+ bar depending on the system.

•   Quartz vessels provide ultra-low trace-metal backgrounds and are preferred when analysing for elements that can leach from fluoropolymer materials at elevated temperatures. However, they are more fragile and expensive.

Before first use, all vessels should be cleaned by running a blank digestion cycle with concentrated HNO₃ to remove residual contamination from manufacturing. Between sample runs, a cleaning cycle with dilute (10%) HNO₃ is standard practice.

Step 4: Digestion Temperature Programme

The temperature profile is the single most important parameter for achieving complete digestion. A typical programme for pharmaceutical matrices follows this pattern:

Table 2: Typical microwave digestion temperature programme for pharmaceutical matrices. Adjust based on matrix complexity and microwave system specifications.

Key considerations:

•   Matrices with high organic loads (botanicals, cellulose-based excipients) may require the extended Phase 3 at 200–220 °C for complete decomposition.

•   Simple APIs (Active Pharmaceutical Ingredients) or water-soluble excipients may digest completely at 180 °C without the extended hold.

•   Never vent vessels while hot. Allow complete cooling before opening to prevent loss of volatile analytes (As, Hg) and to avoid violent pressure release.

•   Monitor pressure during method development. Excessive organic loading can produce dangerous pressure spikes—if this occurs, reduce sample mass or increase H₂O₂ volume.

Step 5: Post-Digestion Handling and Dilution

After the vessels have cooled and been vented:

1. Visually inspect the digest. A clear, colourless to pale yellow solution indicates complete digestion. Any visible particulate, turbidity, or dark colouration suggests incomplete decomposition—the sample should be re-digested with adjusted parameters.

2. Weight to weight dilutions are the most accurate method. Quantitatively transfer the digest to a HNO3 leached LDPE bottle or volumetric flask, rinsing the vessel walls with ultra-pure water (18.2 MΩ·cm).

3. Dilute to a final weight or volume of 50–100 g (mL), depending on the target concentration range and instrument sensitivity. Final acid concentration should be 2–5% v/v HNO₃ for ICP‑MS, or up to 10% v/v for ICP‑OES.

4. If mercury is a target analyte, add gold (Au) stabiliser at 200–500 ppb to all solutions (digests, calibration standards, and rinses) to prevent adsorption losses. For more on element-specific handling, see our paper on USP 232 and ICH Q3D element stability in ICP standards.

The final digest is now ready for analysis by ICP‑OES or ICP‑MS.

Calibration Standards and Matrix Matching

The accuracy of your final result depends not only on the quality of the digestion but on how well your calibration standards match the digest matrix. This means:

•   Acid matching: Calibration standards must be prepared in the same acid type and concentration as the final digest. If your digests are in 2% HNO₃, your standards should be in 2% HNO₃. Mismatched matrices produce systematic bias in ICP‑MS measurements due to differences in nebulisation efficiency and ionisation. See our guidance on handling, calculations, preparation and storage of standards.

•   Use certified reference materials: For USP <232> testing, Inorganic Ventures offers purpose-built USP <232> Class 1 Oral Elemental Impurities standards, Parenteral standards, and Drug Substance & Excipients standards formulated at concentrations aligned with PDE limits. All are NIST-traceable with full uncertainty documentation.

•   Internal standardisation: Adding internal standards (e.g., Ge, In, Bi, Sc) to all samples and calibration solutions compensates for matrix effects and instrument drift during the analytical run. For guidance on selecting the right internal standard, see our article on internal standardization for ICP.

For a full explanation of how to convert ICP results from concentration units to the PDE-based limits defined in USP <232>, read our guide on elemental analysis of pharmaceutical samples using the J value.

Validating Your Microwave Digestion Method Under USP <233>

Before your method can be used for routine testing, USP <233> requires formal validation of the complete preparation-to-analysis workflow. Here is how microwave digestion supports each criterion:

Accuracy: Spike Recovery at the J Value

Prepare spiked samples at the target concentration (the J value, calculated from the PDE limit and the maximum daily dose of the product). Digest alongside unspiked samples and calculate recovery. Microwave digestion routinely achieves 90–110% recoveries for the Big Four elements, well within the 70–150% acceptance range, because the sealed system prevents analyte loss and the aggressive conditions ensure complete matrix decomposition.

Precision: Replicate Consistency

Automated temperature and pressure control in modern microwave systems eliminates the variability inherent in manual hot-plate digestion. Run at least six replicate preparations and calculate the RSD. Values below 10% are readily achievable with a well-optimised microwave method—comfortably meeting the ≤20% USP requirement.

Blank Integrity

Reagent blanks (digestion acid only, processed through the same microwave programme) must show no significant analyte signal above the method detection limit. This verifies that neither the reagents nor the vessels are contributing contamination. If blanks are elevated, suspect reagent purity, vessel carry-over, or laboratory air quality.

For a comprehensive walkthrough of analytical accuracy considerations, see our guide: How to Ensure Accurate Elemental Impurities Testing Results.

Common Pitfalls and How to Avoid Them

•   Excessive sample mass: Overloading vessels with high-organic samples is the most common cause of failed digestions and pressure safety events. Start with 50–100 mg for unknown matrices and scale up cautiously.

•   Inadequate cooling before venting: Opening vessels prematurely releases volatile analytes (especially As and Hg) and poses a safety hazard. Allow the system to cool below 50 °C before venting.

•   Using non-ICP-grade reagents: Standard analytical-grade acids contain enough trace-metal contamination to compromise blank levels at the sub-ppb concentrations relevant to USP <232> testing. Always use ICP-grade or Suprapur reagents.

•   Ignoring vessel cleaning: Cross-contamination between samples is a real risk if vessels are not properly cleaned. Run acid-only cleaning cycles between batches, especially when switching between high-concentration and trace-level samples.

•   Skipping reagent blanks: Every digestion batch must include at least one reagent blank processed through the identical programme. Without blanks, you cannot distinguish analyte signal from contamination.

•   Not accounting for the final acid concentration: If calibration standards are prepared in a different acid concentration than the digest, the resulting matrix mismatch will bias ICP results. Always matrix-match. Our calibration standards guidance covers this in detail.

Frequently Asked Questions

How are pharmaceutical samples prepared for elemental impurities testing?

Pharmaceutical samples are typically prepared using closed-vessel microwave-assisted acid digestion. The sample is weighed into a PTFE or quartz vessel, combined with concentrated nitric acid (and optionally hydrogen peroxide), sealed, and heated to 180–220 °C under pressure. This decomposes the organic matrix and brings all elemental impurities into solution for analysis by ICP‑OES or ICP‑MS. The method must be validated per USP <233> requirements.

What acids are used for microwave digestion of pharmaceutical samples?

The standard reagent is concentrated nitric acid (HNO₃, 65–70%), typically ICP-grade or Suprapur quality. Hydrogen peroxide (H₂O₂, 30%) is often added as a secondary oxidant for high-organic matrices. Hydrochloric acid (HCl) may be used in specific cases to stabilize mercury, but it introduces spectral interferences on arsenic in ICP‑MS and should be avoided unless collision/reaction cell technology is available.

Why is closed-vessel digestion preferred for USP <233> testing?

Closed-vessel digestion is preferred because it prevents the loss of volatile elements—particularly arsenic and mercury—that would escape during open-vessel heating. It also achieves higher temperatures (180–220 °C vs. ~100 °C in open vessels), ensuring complete decomposition of complex pharmaceutical matrices. The sealed environment additionally reduces contamination from airborne particulates.

What temperature is used for microwave digestion of pharmaceuticals?

Most pharmaceutical matrices digest completely at 180 °C with a 10–15 minute hold. Complex matrices with high organic content (botanicals, cellulose-based excipients) may require an extended step at 200–220 °C. The ramp phase typically takes 15–20 minutes, and the entire cycle including cooling is usually complete within 45–60 minutes.

What is the difference between open-vessel and closed-vessel digestion?

Open-vessel digestion heats samples at atmospheric pressure, limiting the temperature to the boiling point of the acid (~100–120 °C). This is slower, less complete for complex matrices, and causes loss of volatile elements like arsenic and mercury. Closed-vessel microwave digestion operates under elevated pressure, reaching 180–220 °C, achieving faster and more complete decomposition with full retention of volatile analytes. For USP compliance testing involving the Class 1 elements, closed-vessel digestion is strongly recommended.

Building a Compliant, Reproducible Workflow

Microwave digestion is not merely a convenience—it is a foundational requirement for producing defensible elemental impurities data under USP <232>, <233>, and <2232>. The combination of complete matrix decomposition, volatile element retention, low contamination risk, and automated reproducibility makes it the natural choice for pharmaceutical QC and R&D laboratories.

The keys to success are straightforward: use ICP-grade reagents, validate your temperature programme for each matrix type, matrix-match your calibration standards, and never skip your blanks. Combined with NIST-traceable certified reference materials formulated for USP compliance, this workflow gives laboratories the confidence to produce accurate, reproducible, and regulatory-ready results.

Need certified reference materials for USP <232> testing? Browse our full range of pharmaceutical compliance standards →